Wereport a 64-year-old male with granulocytopenia and dermatitis due to cyanamide treatment. Weadministered cyanamide for alcoholism. After about one month he suffered from scaly erythema over his whole body and granulocytopenia (granulocyte; 140/jnl) with maturation arrest in bone marrow. After cessation of cyanamide and the start of granulocyte colonystimulating factor administration, the skin eruption ameliorated gradually, and the peripheral blood granulocyte counts increased. Cyanamide showed positive results in the drug lymphocyte stimulation test (198%) and the patch test led to the diagnosis ofgranulocytopenia and dermatitis induced by cyanamide. After restarting glibenclamide and diazepam administration, his granulocytopenia did not reoccur. To our knowledge, this is the first report ofa case with granulocytopenia induced by cyanamide. (Internal Medicine 36: 640-642, 1997) 
Introduction
Cyanamide (Cyanamide®; Yoshitomi Co., Ltd., Tokyo) is a widely used antabuse for alcoholics. The mechanismof cyanamide to discourage alcohol consumption is inhibition of the complete catabolism of alcohol resulting in the accumulation of acetaldehyde (1). Contact dermatitis (2) and liver injury (3) have been reported as adverse effects of this agent. Here, we report a case with granulocytopenia induced by this drug. To our knowledge, this is the first case report on granulocytopenia induced by cyanamide.
Case Report
A 64-year-old male had received oral hypoglycemic agents for diabetes mellitus since 1964, and he had drunk about 360 ml of sake (Japanese spirits containing 16.5% alcohol) every day for 32 years. Because of bad glucose control with a hemoglobin Alc level of 10%due to alcohol intake, westarted to administer 100 mgof cyanamide and 2 mgof diazepam in addition to glibenclamide on July 24, 1995. After 3 weeks, he began to feel general fatigue, and skin eruption emerged over the lower abdomen and thigh. On September 1, he had scaly erythema over his whole body with a body temperature of 37°C and peripheral blood examination showed a leukocyte count of 7,500/jul (neutrophils; 8 1.5%, lymphocytes; 10.9%, monocytes; 6.8%, eosinophils; 0.5%, basophils; 0.3%), a hemoglobin concentration of 15.0 g/dl, and a platelet count of 15.3xlO4/|Lil. He continued to receive cyanamide and the hypoglycemic agent every day, and he was admitted to ourhospital on September 1 3, 1995. He had candidiasis in his oral cavity and scaly erythema overthe whole body ( Fig. 1) with abody temperature of37.7°C.
Peripheral blood examination showed a leukocyte count of 1 ,400/jnl (band cells; 2.5 %, segmented cells; 7.5%, lymphocytes; 44.0%, monocytes; 45%, eosinophils; 0%, basophils; 0%), a hemoglobin concentration of 13.8 g/dl, and a platelet count of 14.7x104/jll1-The CRP level was 0.3 mg/ml, and IgE level was 156 U/ml. Antinuclear antibody test was negative. Bone marrow examination showednormocellular marrowwith maturation arrest (Fig. 2 ). As he had no history of recurrent infections, we diagnosed as drug-induced granulocytopenia and dermatitis. We ceased all medication including glibenclamide, cyanamide, and diazepam, and we started the subcutaneous administration of granulocyte colony-stimulating factor at a daily dose of 75 jig. Skin eruption ameliorated gradually, and after 6 days of a lministration, the leukocyte count increased to 7,900/jnl with 67% granulocytes. Drug lymphocyte stimulation test was positive for cyanamide (198%) and negative for diazepam (125%) and glibenclamide (1 12%). In addition, the results of the patch test were also positive for cyanamide ( Fig. 3) and negative for diazepam and glibenclamide. After 2 days of patch test of cyanamide, eosinophils in peripheral blood increased to Granulocytopenia due to Cyanamide 19.8%. Thus, the diagnosis of granulocytopenia and dermatitis induced by cyanamide was made. After 2 months he had no recurrence of granulocytopenia while receiving glibenclamide and diazepam (Fig. 4 ).
Discussion
Wepresent a case with skin eruption and granulocytopenia during cyanamide treatment for alcoholism. Cessation of the drug administration ameliorated the skin eruption and granulocytopenia, and both drug lymphocyte test and patch test were positive for cyanamide. These findings led us to the diagnosis of dermatitis and granulocytopenia induced by cyanamide. The mechanismof exfoliative erythema is related to a type IV immunereaction. Contact dermatitis was reported as a adverse of cyanamide, and its mechanismis also related to a type IV immunereaction. In addition the patch test was positive for cyanamide in the present case. Thus, exfoliative erythema in this case seems to be the result of a type IV immunereaction against cyanamide. On the other hand, for the causes of druginduced granulocytopenia, known are immune mechanism, e.g. in Quinidine (4) and non-immune mechanisms, e.g. anti-thyroid medication (5) . Here, since the drug lymphocyte stimulation test was positive for cyanamide, an immunemechanism against the drug seemed to be involved also in the granulocytopenia in the present case. In addition, Coombs' test was negative, this granulocytopenia seemed to be a case of Type IV reaction. To our knowledge, this is the first report of a case with granulocytopenia induced by this agent. It is necessary to pay particular attention whenusing cyanamide. y Scaly erythema^^^^^^F igure 4. Clinical course. Shaded area indicates the granulocyte counts, and open area indicates leukocytes. All medication was ceased on September 13, 1995 and the administration of granulocyte colony-stimulating factor was started; then scaly erythema and granulocytopenia were ameliorated.
